SummaryAdministration of cathelicidin exerts effective antifibrogenic effects in colitis associated intestinal fibrosis. Cathelicidin inhibits transforming growth factor β1-induced collagen expression in fibroblasts. The antifibrogenic effect is extracellular-regulated kinase pathway dependent.Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis, is manifested by chronic inflammation of the gastrointestinal tract with significant morbidity and at times life-threatening complications.[@bib1] Patients with chronic CD often develop transmural luminal narrowing and form strictures caused by excessive extracellular matrix deposition.[@bib2], [@bib3] The mechanisms of intestinal fibrosis are complex and not well understood. Transforming growth factor-β1 (TGF-β1) levels are often higher in the mucosa overlying CD strictures compared with nonstrictured gut.[@bib2] Therapies for fibrosis are ineffective, and surgical resection is often required.[@bib2] Approximately 75% of CD patients eventually undergo surgery, most frequently because of intestinal fibrosis.[@bib3] Therapy with anti--tumor necrosis factor α (anti-TNFα) monoclonal antibodies can effectively reduce inflammation but may not prevent or reverse fibrosis in CD patients.[@bib4] Previous studies also have shown that inhibition of TGF-β1 reduces colonic fibrosis in a mouse chronic colitis model.[@bib5]

Cathelicidins (LL-37 in humans and mCRAMP in mice) represent a family of endogenous antimicrobial peptides mediating part of the innate immune response that protects the host from infection.[@bib5] Several studies support the importance of cathelicidins in the pathogenesis of various disease states. Cathelicidin-deficient (*Camp*^−/−^) mice are more susceptible to infections[@bib6] and have reduced angiogenesis and wound healing.[@bib7], [@bib8] Park et al[@bib9] also showed that LL-37 reduces collagen synthesis in dermal fibroblasts, suggesting a potential role for cathelicidins in reducing fibrosis. Intracolonic administration of mCRAMP reduces the severity of dextran sulfate (DSS)-mediated acute colitis in mice,[@bib10] and *Camp*^−/−^ mice have exacerbated acute DSS-induced colitis.[@bib11] In addition, cathelicidin effectively reduces *Clostridium difficile*--mediated colitis and acute *C difficile* toxin A--induced enteritis in mice.[@bib12] Despite its potent anti-inflammatory effects in acute colitis, the potential role of cathelicidin in the development and progress of chronic colitis has not been explored, and the possibility that cathelicidins modulate intestinal fibrosis has never been studied.

Here we used the well-established chronic trinitrobenzene sulphonic acid (TNBS)-induced colitis mouse model as well as the *Salmonella-*mediated cecal inflammation model to study intestinal fibrosis associated with these models.[@bib13], [@bib14] We found that intracolonic peptide or intravenous lentiviral (LV) administration of cathelicidin attenuates colitis-associated intestinal fibrosis and inflammation in vivo. LL-37 reduces collagen expression induced by TGF-β1 and insulin-like growth factor 1 (IGF-1) in human colonic fibroblasts in vitro. Our results also indicate that reduced collagen expression in response to cathelicidin is mediated via extracellular signal-regulated kinase (ERK) activation in these cells.

Materials and Methods {#sec1}
=====================

Cell Cultures {#sec1.1}
-------------

Human CCD-18Co colonic fibroblasts (2 × 10^6^ cells/plate) were cultured in minimal essential medium Eagle's medium (American Type Culture Collection, Manassas, VA) containing 10% fetal bovine serum (Invitrogen/Life Technologies, Carlsbad, CA) and 1% penicillin/streptomycin (Invitrogen).[@bib15] Human primary normal intestinal fibroblasts (three normal and two CD patients) were isolated as previously described elsewhere.[@bib16] Cells (2 × 10^6^ cells/plate) were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 1% penicillin/streptomycin and were serum starved overnight before experiments. LL-37 peptide was purchased from Biopeptide (San Diego, CA). TGF-β1, IGF-1, proinflammatory cytokine cocktail (TNFα, IL-1β, and interferon-γ, 10 ng/mL each), U0126 (1,4-diamino-2,3-dicyano-1,4-*bis*\[2-aminophenylthio\]butadiene) and PD98059 (2-(2′-amino-3′-methoxyphenyl)-oxanaphthalen-4-one) were purchased from Fisher Scientific (Pittsburgh, PA). LL-37, TGF-β1, IGF-1, and the proinflammatory cytokine cocktail were dissolved in trifluoroacetic acid (TFA) 0.1% as the vehicle solution. PD98059 and U0126 were dissolved in dimethyl sulfoxide. Human primary intestinal fibroblasts from normal subjects and CD patients and cultured human colonic CCD-18Co fibroblasts responded to TGF-β1 and/or IGF-1 differently. Based on preliminary experiments, we used two different conditions (TGF-β1 alone and TGF-β1 + IGF-1) to stimulate collagen expression. IGF-1 alone was not sufficient to induce collagen expression in all the fibroblasts we used (data not shown).

Trinitrobenzene Sulphonic Acid Chronic Colitis Model {#sec1.2}
----------------------------------------------------

*Camp*^−/−^ mice in C57BL/6J strain were obtained from Dr. Richard Gallo at the University of California--San Diego and were bred and maintained at the University of California--Los Angeles (UCLA) animal facility under standard environmental conditions. The animal studies were approved by the animal research committee of UCLA. Chronic TNBS-associated colitis was induced as previously reported elsewhere.[@bib14], [@bib15] Mice (8--9 weeks old) were injected with TNBS solution or 30% ethanol (50 μL) intracolonically for 5 weeks as illustrated in [Figure 1](#fig1){ref-type="fig"} *A*. Intracolonic administration was achieved by inserting a polyethylene (PE10) catheter 3 cm into rectum under light isoflurane anesthesia. A group of mice were injected with 5 mg/kg of mCRAMP intracolonically every 3 days starting at week 5. Another mouse group were injected with *Camp*-expressing lentivirus (1 × 10^7^ infectious units/mouse) or hemagglutinin (HA)-expressing lentivirus intravenously once, starting at week 5 as illustrated in [Figure 6](#fig6){ref-type="fig"} *A*. Colonic tissues were obtained at week 6 or 7 after carbon dioxide euthanasia.

*Salmonella* Infection Model {#sec1.3}
----------------------------

Wild-type mice in 129Sv/J strain were obtained from Jackson Laboratory (Bar Harbor, ME) and were maintained at the UCLA animal facility under standard environmental conditions. Each mouse was administered 20 mg of streptomycin by oral gavage. The *Salmonella typhimurium* SL1344 strain was obtained from Dr. Richard Issacson (University of Minnesota) and was cultured in Lysogeny broth (LB broth) for 48 hours. At 24 hours later, the mice were given *Salmonella typhimurium* SL1344 strain 1 × 10^8^ cfu or LB broth in 100 μL by oral gavage as previously described elsewhere.[@bib13] Some groups were injected with *Camp*-expressing lentivirus (1 × 10^7^ infectious units/mouse) or HA lentivirus intravenously once starting on day 11, as illustrated in [Figure 8](#fig8){ref-type="fig"}*A*. Cecal tissues were obtained on day 21 after carbon dioxide euthanasia.

Virus Production and Transduction {#sec1.4}
---------------------------------

The generation of cathelicidin-expressing lentivirus was performed by UCLA vector core facility. Lentivirus-based vectors encoding CRAMP were generated by transient cotransfection of human embryonic kidney 293T (HEK293T) cells with a three-plasmid combination, as described previously elsewhere, with slight modifications.[@bib17] Briefly, 8 × T175 flasks of nonconfluent HEK293T cells were cotransfected with 39 μg pMDLg/pRRE, 21 μg of pMDG (encoding the VSV-G envelope), 15 μg of pRSV-REV, and 60 μg pRRL-CMV-CRAMP-Ires green fluorescent protein (GFP) by the CaPi-DNA coprecipitation method.[@bib18], [@bib19] The plasmid vectors were kindly provided by Dr. Luigi Naldini (University of Torino, Italy). The next day, the medium was adjusted to make a final concentration of 10 mM sodium butyrate, and the cells were incubated for 5 hours to obtain high-titer virus production as previously described elsewhere.[@bib20] After the 5-hour incubation, the cells were washed and incubated in fresh medium without sodium butyrate. Conditioned medium was harvested 16 hours later and passed through 0.45-mm filters. The harvested supernatant was transferred into a centrifuge tube and layered on top of a 10-mL 20% (w/v) sucrose cushion. The tubes were centrifuged using a SW28 rotor (Beckman Coulter, Brea, CA) for 2 hours at 22,000 rpm at 4°C. The virus-containing pellet was resuspended by gentle agitation in an appropriate volume of Dulbecco's phosphate-buffered saline, followed by a short centrifugation step (5 minutes at 16,000*g*) to pellet debris. Finally, the opaque pellet was transferred to a new tube. The biological titer of the LVs carrying the enhanced green fluorescent protein (eGFP) reporter was analyzed by transduction of HEK293T cells followed by flow cytometry and infectious particles/mL were calculated as previously described elsewhere.[@bib21]

Histologic Scoring {#sec1.5}
------------------

Murine colonic tissues were fixed, sectioned, and stained with H&E. Microphotographs at 200× magnification were recorded at multiple locations and analyzed by two investigators in a blinded manner, scoring the specimens on a 0--12 scale for chronic TNBS colitis as previously described elsewhere.[@bib22] The fibrosis score for both TNBS and *Salmonella* models was determined as previously described elsewhere.[@bib23] In brief, several mucosal and submucosal locations for each Masson trichrome--stained slide were evaluated on a 0--3 scale (0 = no fibrosis, 1 = mild fibrosis, 2 = moderate fibrosis, and 3 = severe fibrosis).

Mouse TNF-α, Mouse and Human TGF-β1 Enzyme-Linked Immunosorbent Assay {#sec1.6}
---------------------------------------------------------------------

The levels of mouse TNF-α (DY410), mouse TGF-β1 (DY1679) and human TGF-β1 (DY240) of R&D Systems (Minneapolis, MN) were measured by the enzyme-linked immunosorbent assay kits according to manufacturer's instructions.

Quantitative Real-Time Reverse-Transcription Polymerase Chain Reaction {#sec1.7}
----------------------------------------------------------------------

Total RNA was isolated with the RNeasy kit (Qiagen, Valencia, CA) and reversed transcribed into cDNA by a Superscript III kit (no. 11752; Invitrogen). Quantitative reverse-transcription polymerase chain reaction (RT-PCR) reactions were run with an ABI Prism 7500 Fast sequence detector system (Applied Biosystems, Foster City, CA) as we have previously described elsewhere.[@bib15] The levels of mRNA were determined by using cataloged primers (Invitrogen) for human *COL1A2* (Hs01028956_m1), *CAMP* (Hs00189038_m1), mouse *vimentin* (Mm01333430_m1), *18S* (Hs99999901_s1) and mouse *Col1a2* (Mm01309565_m1), *Camp* (Mm00438285_m1), *Tgf-β1* (Mm01178820_m1), *Tnfα* (Mm00443259_g1), and *Gapdh* (Mm99999915_g1). Results were expressed as relative fold difference.

Masson Trichrome Staining {#sec1.8}
-------------------------

Staining of collagen deposition of colonic tissue sections was performed by Masson Trichrome staining kit (HT-10; Sigma-Aldrich, St. Louis, MO) and Bouin solution (HT-10132) as previously described elsewhere.[@bib15]

Immunofluorescence Staining {#sec1.9}
---------------------------

Frozen mouse colonic tissues were embedded in optimum cutting temperature solution and fixed in acetone. After incubation with blocking buffer, slides were incubated with primary antibodies including rabbit polyclonal anticollagen sc-28655, rabbit polyclonal anti-PCNA (anti-proliferating cell nuclear antigen) sc-7907, or goat polyclonal antivimentin sc-7557 (1:50 dilution) for 2 hours at room temperature, washed with phosphate-buffered saline and incubated with fluorescent-conjugated secondary antibodies, including donkey anti-rabbit Texas Red sc-2784 and bovine anti-goat FITC sc-2348, for 1 hour (1:100 dilution). Slides were then rinsed and mounted with 4,6-diamidino-2-phenylindole (DAPI) mounting solution. Images were analyzed with a AX10 confocal microscope (Carl Zeiss, Thornwood, NY).

Immunohistochemistry {#sec1.10}
--------------------

Colon tissues were fixed in 4% paraformaldehyde and embedded in paraffin. After incubation with blocking buffer, the sections were incubated with a goat polyclonal antivimentin antibody (sc-7557, 1:50 dilution; Santa Cruz Biotechnology, Santa Cruz, CA), a rabbit polyclonal anti-F4/80 antibody (sc-26643-R, 1:50 dilution; Santa Cruz Biotechnology), or a rabbit polyclonal anti-phospho-ERK antibody (no. 4370, 1:50 dilution; Cell Signaling Technologies, Danvers, MA) overnight at 4°C. After washing, the sections were incubated with donkey anti-goat IgG or bovine anti-rabbit IgG, and the slides were stained with an ABC kit for color development (sc-2018; Santa Cruz Biotechnology). Immunohistochemistry was assisted by Translational Pathology Core Laboratory (TPCL) of UCLA. Images were analyzed with a Zeiss AX10 microscope at magnification of 200×.

Western Blot Analyses {#sec1.11}
---------------------

Cells were lysed in radioimmunoprecipitation assay buffer with proteinase inhibitor cocktail (Cell Signaling Technologies). Equal amounts of cell extracts were fractionated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis, and proteins were transferred onto nitrocellulose membranes (400 mA for 1.5 hours at 4°C; Bio-Rad Laboratories, Hercules, CA). Membranes were blocked in 5% nonfat milk in TBST (50 mM Tris, pH 7.5, 0.15M NaCl, 0.05% Tween 20), and then were incubated with antibodies against phospho-extracellular signal-regulated kinase (phospho-ERK) (no. 4370), β-tubulin (no. 2146; Cell Signaling Technologies), phospho-epidermal growth factor receptor (phospho-EGFR) (no. sc12351; Santa Cruz Biotechnology), pro-COL1A1 (no. SP1D8; Development Studies Hybridoma Bank, Iowa City, IA). Horseradish peroxidase-labeled antibodies were detected by chemiluminescence (Fisher Scientific, Pittsburgh, PA), and the signals were captured using the luminescent image analyzer LAS4000 (Fujifilm, Tokyo, Japan).

Statistical Analyses {#sec1.12}
--------------------

Results were expressed as mean ± standard error of the mean (SEM) and were analyzed by using the Prism professional statistics software program (GraphPad, San Diego, CA). Unpaired Student *t* tests were used for intergroup comparisons. *P* values of statistically significant differences are shown in each figure.

Results {#sec2}
=======

Cathelicidin Reduces Chronic, TNBS-Induced Colitis in Mice {#sec2.1}
----------------------------------------------------------

We have previously shown that cathelicidins have anti-inflammatory effects against DSS-induced colitis and *C difficile* infection in mice.[@bib11], [@bib12] To investigate the role of cathelicidin in chronic colitis, mice were administered a low dose of TNBS intracolonically every week as previously described elsewhere.[@bib14], [@bib15] The experimental design of these experiments is illustrated in [Figure 1](#fig1){ref-type="fig"}*A*. After 7 weeks, the body weight of the TNBS-treated mice was statistically significantly lower (*P* = .045) compared with that of ethanol-treated (control) mice ([Figure 1](#fig1){ref-type="fig"}*B*). Intracolonic administration of the mCRAMP peptide to TNBS-exposed mice restored their body weight loss to levels similar to those of the control mice (*P* = .0178, [Figure 1](#fig1){ref-type="fig"}*B*). Moreover, chronic TNBS administration induced colonic tissue damage with statistically significantly higher (*P* = .001) histologic scores compared with the damage induced in control mice ([Figure 1](#fig1){ref-type="fig"}*C* and *D*). Intracolonic mCRAMP administration statistically significantly reduced the colonic histology score (*P* = .03) in TNBS-treated mice ([Figures 1](#fig1){ref-type="fig"}*D*).

TNBS caused a statistically significant increase of the colonic proinflammatory cytokine tumor necrosis factor α (Tnfα) mRNA levels (*P* = .0344; [Figure 1](#fig1){ref-type="fig"}*E*), which were statistically significantly reduced by mCRAMP administration (*P* = .046, [Figure 1](#fig1){ref-type="fig"}*E*). Intracolonic TNBS also increased colonic Tgf-β1 mRNA expression; intracolonic administration of cathelicidin did not alter this response ([Figure 1](#fig1){ref-type="fig"}*F*). However, intracolonic mCRAMP did not change the increased colonic F4/80-positive macrophage infiltration in TNBS-treated mice ([Figure 2](#fig2){ref-type="fig"}). Thus, intracolonic administration of cathelicidin reduced chronic experimental colitis in an IBD mouse model, consistent with our results in the *C difficile* infection model of colitis.[@bib12]

Cathelicidin Reduces Chronic Colitis-Associated Collagen Expression {#sec2.2}
-------------------------------------------------------------------

Intestinal fibrosis with stricture formation is an important complication in CD patients.[@bib3] We next evaluated the effect of intracolonic cathelicidin in TNBS colitis-associated colonic fibrosis with Masson trichrome staining for collagen formation. We found increased collagen deposition in the colon of TNBS-treated mice, both in the mucosa and submucosa, compared with control mice ([Figure 3](#fig3){ref-type="fig"}*A*), which was in line with previous observations.[@bib14], [@bib15] Increased fibrosis was also reflected by an increased fibrosis score ([Figure 3](#fig3){ref-type="fig"}*B*). Moreover, compared with ethanol treatment, chronic TNBS administration increased the collagen Col1a2 mRNA colonic expression (*P* = .0376, [Figure 3](#fig3){ref-type="fig"}*C*) that was statistically significantly reduced by intracolonic mCRAMP administration (*P* = .0364, [Figure 3](#fig3){ref-type="fig"}*C*), suggesting antifibrogenic effects. Double immunofluorescence staining showed increased colonic collagen protein expression in and around vimentin-expressing fibroblasts in TNBS-treated mice ([Figure 4](#fig4){ref-type="fig"}). Colocalization of collagen and vimentin indicates that fibroblasts are main sources of collagen expression. Intracolonic mCRAMP peptide administration also reduced collagen expression in and around colonic fibroblasts of TNBS-treated mice ([Figure 4](#fig4){ref-type="fig"}).

On the other hand, cathelicidin-deficient mice showed similar colonic histologic damage ([Figure 5](#fig5){ref-type="fig"}*A* and *B*), collagen expression ([Figure 5](#fig5){ref-type="fig"}*C* and *D*), or TNFα protein levels ([Figure 5](#fig5){ref-type="fig"}*E*) as the wild-type mice in chronic TNBS colitis. Our data also indicate that expression of endogenous colonic cathelicidin in wild-type mice was not induced during chronic TNBS colitis ([Figure 6](#fig6){ref-type="fig"}*B*). However, intracolonic cathelicidin mCRAMP administration reduced colonic tissue damage ([Figure 5](#fig5){ref-type="fig"}*A* and *B*) and exerted antifibrogenic effects in TNBS-treated *Camp*^−/−^ mice ([Figure 5](#fig5){ref-type="fig"}*C* and *D*).

Lentiviral Expression of Cathelicidin Reduces Colitis-Associated Intestinal Fibrosis {#sec2.3}
------------------------------------------------------------------------------------

To further examine the effects of cathelicidin in colitis-associated fibrosis, we injected intravenously cathelicidin-overexpressing lentiviruses and determined their effects in the chronic TNBS-associated model of colitis and colonic fibrosis using the experimental approach shown in [Figure 6](#fig6){ref-type="fig"}*A*. We found that intravenous administration of cathelicidin-expressing lentiviruses increased colonic cathelicidin mRNA levels compared with the injection of control lentiviruses ([Figure 6](#fig6){ref-type="fig"}*B*). Moreover, injection of cathelicidin-overexpressing lentiviruses significantly reduced the histologic damage and histology scores in response to chronic TNBS administration ([Figure 6](#fig6){ref-type="fig"}*C* and *D*) without affecting the body weight changes in response to TNBS ([Figure 6](#fig6){ref-type="fig"}*E*). Lentiviral overexpression of cathelicidin also inhibited TNBS-induced collagen deposition in the colon, as reflected by a statistically significant reduction in the colonic fibrosis score (*P* = .0001, [Figure 7](#fig7){ref-type="fig"}*A* and *B*) and reduced colonic collagen Col1a2 mRNA expression (*P* = .0497, [Figure 7](#fig7){ref-type="fig"}*C*).

Lentiviral Expression of Cathelicidin Reduces Cecal Fibrosis during *Salmonella* Infection {#sec2.4}
------------------------------------------------------------------------------------------

*Salmonella* induces intestinal inflammation and fibrosis in a T~H~1 and T~H~17-dependent manner.[@bib13] Thus, we next examined whether injection of LV-overexpressing cathelicidin has any effect on *Salmonella*-induced fibrosis using the experimental design shown in [Figure 8](#fig8){ref-type="fig"}*A*. Interestingly, *Salmonella* infection by itself resulted in increased mRNA levels of cecal cathelicidin (*P* = .0001; [Figure 8](#fig8){ref-type="fig"}*B*), which was further increased by injection of cathelicidin-expressing lentiviruses in the inflamed cecum (*P* = .0317, [Figure 8](#fig8){ref-type="fig"}*B*). As shown by H&E staining, *Salmonella* caused severe cecal inflammation and tissue damage that was reduced by lentiviral cathelicidin expression ([Figure 8](#fig8){ref-type="fig"}*C* and *D*). Cathelicidin overexpressing lentiviruses also statistically significantly reduced *Salmonella*-induced proinflammatory cytokine Tnfα mRNA expression (*P* = .0107) ([Figure 8](#fig8){ref-type="fig"}*E*). No change in body weight was observed in any of the *Salmonella*-infected groups ([Figure 9](#fig9){ref-type="fig"}*A*).

Masson trichrome staining indicated strong cecal collagen deposition in *Salmonella*-infected mice, which was diminished by LV cathelicidin overexpression ([Figure 9](#fig9){ref-type="fig"}*B*), reflected by a statistically significant reduction in the fibrosis score (*P* = .0001, [Figure 9](#fig9){ref-type="fig"}*C*) and cecal collagen mRNA expression (*P* = .0251, [Figure 9](#fig9){ref-type="fig"}*D*). Overexpression of cathelicidin in *Salmonella*-infected mice did not statistically significantly affect cecal Tgf-β1 mRNA expression ([Figure 9](#fig9){ref-type="fig"}*E*).

Cathelicidin Inhibits Collagen Expression Induced by TGF-β1 and IGF-1 in Human Intestinal Fibroblasts {#sec2.5}
-----------------------------------------------------------------------------------------------------

In the mucosa of CD strictures, TGF-β1 and IGF-1 stimulate collagen expression in intestinal fibroblasts, leading to fibrosis.[@bib3] Previous studies indicated that TGF-β1 stimulates collagen synthesis in lung and dermal fibroblasts.[@bib24] To study the antifibrogenic mechanism of cathelicidin, we coincubated human primary normal intestinal fibroblasts with TGF-β1 (5 ng/mL) together with human cathelicidin (LL-37, 5 μM). TGF-β1 alone stimulated procollagen 1A1 protein expression (*P* = .0001) in human primary normal intestinal fibroblasts after 48 hours ([Figure 10](#fig10){ref-type="fig"}*A* and *B*). Coincubation with human cathelicidin statistically significantly reduced TGF-β1-stimulated (*P* = .0001) procollagen 1A1 protein expression ([Figure 10](#fig10){ref-type="fig"}*A* and *B*). Similarly, LL-37 statistically significantly inhibited TGF-β1-stimulated COL1A2 mRNA expression in human primary intestinal fibroblasts ([Figure 10](#fig10){ref-type="fig"}*C*) and also reduced procollagen 1A1 protein expression induced by TGF-β1 in human primary intestinal fibroblasts isolated from CD patients ([Figure 10](#fig10){ref-type="fig"}*D* and *E*). Moreover, in cultured human colonic CCD-18Co fibroblasts, cathelicidin inhibited TGF-β1- and/or IGF-1-induced collagen protein synthesis ([Figure 11](#fig11){ref-type="fig"}).

Cathelicidin Reduces Collagen Expression in Human Colonic Fibroblasts via ERK Activation {#sec2.6}
----------------------------------------------------------------------------------------

ERK activation has been shown to be involved in the antifibrogenic effects of cathelicidin in dermal fibroblasts.[@bib9] We hypothesized that ERK may represent a pathway modulating the antifibrogenic effects of cathelicidin in primary intestinal fibroblasts. We found that LL-37-induced inhibition of TGF-β1-mediated collagen protein expression in human primary normal intestinal fibroblasts was partially reversed by pretreatment of cells with the ERK inhibitors PD98059 and U0126 ([Figure 12](#fig12){ref-type="fig"}*A*). Moreover, cathelicidin induced ERK phosphorylation in a concentration-dependent manner regardless of the presence of TGF-β1 or IGF-1 in human normal primary intestinal fibroblasts ([Figure 12](#fig12){ref-type="fig"}*B*). Consistent with these finding, cathelicidin-induced ERK phosphorylation (addition of EGF serving as a positive control), but not EGFR phosphorylation in human CCD-18Co colonic fibroblasts ([Figure 13](#fig13){ref-type="fig"}*A*). Addition of EGF also augmented the antifibrogenic effects of cathelicidin in both human primary intestinal fibroblasts obtained from CD patients and human CCD-18Co colonic fibroblasts ([Figure 13](#fig13){ref-type="fig"}*B*--*E*). These results suggest that cathelicidin inhibits fibrogenesis via an ERK-dependent pathway in native human colonic fibroblasts.

To confirm cathelicidin mediated ERK activation in vivo, we determined ERK phosphorylation in submucosal tissues of colons and cecum where most fibroblasts are populated. We found the submucosal tissues of normal, TNBS-treated, or *Salmonella*-infected mice had a low expression of phosphorylated ERK ([Figure 14](#fig14){ref-type="fig"}*A* and *B*). Both intracolonic mCRAMP peptide administration and intravenous *Camp*-expressing lentivirus administration activated colonic or cecal ERK phosphorylation in the TNBS or *Salmonella* model of intestinal fibrosis ([Figure 14](#fig14){ref-type="fig"}*A* and *B*).

Discussion {#sec3}
==========

We and others have previously shown that the antimicrobial peptide cathelicidin possesses potent anti-inflammatory activities against acute intestinal inflammation.[@bib10], [@bib11], [@bib12] Consistent with these findings, our results using the models of chronic TNBS colitis and *Salmonella* infection and two different approaches---intracolonic administration of cathelicidin peptide and intravenous injection of cathelicidin-expressing lentiviruses---demonstrate that cathelicidin exerts significant anti-inflammatory effects, including reduction of mucosal Tnfα protein or mRNA expression ([Figures 1](#fig1){ref-type="fig"}*E*, [5](#fig5){ref-type="fig"}*E*, and [8](#fig8){ref-type="fig"}*E*). Both approaches also lead to substantial improvement of histologic evidence of colitis in both animal models ([Figures 1](#fig1){ref-type="fig"}*D*, [5](#fig5){ref-type="fig"}*B*, [6](#fig6){ref-type="fig"}*D*, and [8](#fig8){ref-type="fig"}*D*). Taken together with previous findings,[@bib10], [@bib11], [@bib12] our results demonstrate a role for exogenous administration of cathelicidin against both acute and chronic IBD-related colitis as well as infectious colitis of different etiologies. Most importantly, we report here that cathelicidin inhibits colitis-associated colonic fibrosis in chronic TNBS and *Salmonella* infection models in vivo and in human intestinal fibroblasts in vitro, suggesting that exogenous cathelicidin may represent an effective approach in inhibiting colitis-associated fibrosis.

The role of antimicrobial peptides or proteins, including cathelicidins, in colitis-associated intestinal fibrosis or stricture formation has never been reported. We report here that cathelicidin inhibits colitis-associated colonic fibrosis in vivo and substantially reduces TGF-β1- and/or IGF-1-mediated collagen protein synthesis in human intestinal fibroblasts isolated from three normal subjects and two CD patients ([Figure 10](#fig10){ref-type="fig"}*A*--*E*) as well as in human colonic CCD-18Co fibroblasts ([Figure 11](#fig11){ref-type="fig"}).

In rats, systemic blockade of putative cathelicidin receptor P2X7 by A740003 \[*N*-(1-(\[(cyanoimino)(5-quinolinylamino) methyl\] amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide\] and brilliant blue G prevented TNBS-induced colitis[@bib25] while A438079 \[3-\[\[5-(2,3-dichlorophenyl)-1*H*-tetrazol-1-yl\]methyl\]pyridine\], another P2X7 inhibitor, reduced mouse liver fibrosis.[@bib26] Another putative cathelicidin receptor formyl peptide receptor-like 1 (FPRL1) was found to mediate LL-37-induced collagen production in human lung fibroblasts.[@bib27] However, the antifibrogenic effect of LL-37 in human intestinal fibroblasts was not altered by pretreatment with the FPRL1 antagonist WRW4 or the P2X7 antagonist KN62 (data not shown), suggesting that the antifibrogenic effects of cathelicidin do not depend on these two putative cathelicidin receptors.

This antifibrogenic effect likely involves an ERK-dependent mechanism as it can be blocked by the mitogen-activated protein kinase 1 (MEK1) inhibitor PD98059 and the MEK1/2 inhibitor U0126 ([Figure 12](#fig12){ref-type="fig"}*A*). Cathelicidin induces ERK phosphorylation in human normal intestinal fibroblasts and human CCD-18Co colonic fibroblasts ([Figures 12](#fig12){ref-type="fig"}*B* and [13](#fig13){ref-type="fig"}*A*). Specifically, the effects of cathelicidin in collagen synthesis appear to be mediated by MEK1, as the MEK1 inhibitor PD98059 was sufficient to reverse LL-37-mediated suppression of TGF-β1-induced collagen synthesis ([Figure 12](#fig12){ref-type="fig"}*A*). These results confirm that the antifibrogenic effects of cathelicidin in intestinal fibroblasts are ERK-dependent and are consistent with a previous report demonstrating that the antifibrogenic mechanism of cathelicidin in dermal fibroblasts involves ERK activation.[@bib9]

Cathelicidin did not affect protein expression of the fibrogenic TGF-β1 in CCD-18Co colonic fibroblasts, even in the presence of a proinflammatory cytokine cocktail (TNFα, IL-1β, and interferon-γ) ([Figure 15](#fig15){ref-type="fig"}*A* and *B*). Moreover, intracolonic cathelicidin administration or injection of cathelicidin-overexpressing lentiviruses did not affect intestinal TGF-β1 mRNA expression in both TNBS and *Salmonella* fibrosis mouse models ([Figures 1](#fig1){ref-type="fig"}*F* and [9](#fig9){ref-type="fig"}*E*). These results suggest that the antifibrogenic effects of cathelicidin are independent of the classic TGF-β1-mediated profibrogenic events.

On the other hand, cathelicidin treatment did not induce fibroblast cell proliferation in vitro, and did not affect colonic or cecal expression of the fibroblast marker vimentin expression (data not shown) and proliferating cell nuclear antigen staining ([Supplementary Figure 1](#appsec1){ref-type="sec"}) in our in vivo models. We did not observe colonic apoptosis (terminal deoxynucleotidyl transferase--mediated deoxyuridine triphosphate nick-end labeling assay) after intracolonic or intravenous cathelicidin administration (data not shown), suggesting that cathelicidin is unlikely to cause tissue damage in the intestine.

Despite the positive antifibrogenic effects of cathelicidin administration, TNBS-treated cathelicidin-deficient mice did not show additional colonic fibrosis or tissue damage compared with TNBS-treated wild-type mice ([Figure 5](#fig5){ref-type="fig"}). The lack of increased endogenous cathelicidin expression ([Figure 6](#fig6){ref-type="fig"}*B*) may be related to low levels of inflammation seen in this chronic TNBS-induced model as reflected by low colonic TNFα protein level ([Figure 5](#fig5){ref-type="fig"}*E*). Colonic TNFα levels were similar among TNBS treated wild-type and *Camp*^−/−^ mice ([Figure 5](#fig5){ref-type="fig"}*E*). Although colonic cathelicidin mRNA expression is increased in acute DSS-induced colitis,[@bib11] intestinal cathelicidin mRNA expression is not altered in CD patients.[@bib28]

Several studies have underlined the importance of the bacterial composition of the intestinal flora in IBD pathophysiology and epithelial barrier integrity. Along these lines, the ability of cathelicidin to alter the gut microflora may be associated with the antifibrogenic effects reported here.[@bib10], [@bib11] Because the microflora composition associated with intestinal fibrosis has not been identified in animal or human colon, future studies are necessary to explore this possibility.

In summary, our report provides novel evidence for an antifibrogenic effect of cathelicidin in vivo and in vitro. Our results strongly suggest that cathelicidin administration may be a novel approach to prevent or treat IBD, and IBD-related colonic fibrosis.

Supplementary Material {#appsec1}
======================

Supplementary Figure 1**Cathelicidin did not affect cell proliferation in colonic tissues.** Immunofluorescence staining of cell proliferation marker PCNA (red), fibroblast marker vimentin (green) and nuclei DAPI (blue). In TNBS+TFA, weak red PCNA staining was observed in and around fibroblasts that were identified by green color. Overlapping images of red PCNA staining, green vimentin staining and blue nuclear staining are shown in lower right corner. All groups had low level of PCNA staining in and around vimentin green staining, indicating low cell proliferation in colonic fibroblasts.
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![**Cathelicidin peptide administration reduces colonic inflammation in TNBS-mediated chronic colitis in mice.** (*A*) Illustration of experimental plan of TNBS-mediated chronic colitis. Mice were injected with increasing doses of TNBS solution intracolonically once a week for 6 weeks. Some mice received intracolonic injection of mCRAMP peptide or vehicle solution 0.1% of trifluroacetic acid (control) starting from the fifth TNBS injection. Colonic changes were evaluated 2 weeks after the last TNBS injection. (*B*) Percentage of body weight change of different groups (from week 0 to week 7). All ethanol-treated groups had approximately 20% body weight gain. TNBS-treated wild-type mice had statistically significantly less body weight gain compared with ethanol control (*P* = .045). Administration of mCRAMP peptide to TNBS-treated wild-type partially restored the body weight gain (*P* = .0178). (*C*) Representative H&E images of colonic tissues. Large arrows show immune cell infiltration. Small arrows show collagen deposition and mucosal transformation with altered cryptal architecture. (*D*) Histology score was based on H&E staining images of colonic tissues. TNBS treatment in mice led to increased tissue damage with a statistically significantly higher histology score (*P* = .001) compared with the ethanol control. Treatment with mCRAMP statistically significantly reduced the histology score (*P* = .03). (*E*) TNBS treatment statistically significantly induced colonic proinflammatory cytokine Tnfα mRNA (*P* = .0344) expression. Intracolonic mCRAMP administration statistically significantly reduced TNBS-induced mRNA (*P* = .046) expression in mice. (*F*) Colonic Tgf-β1 mRNA expression in mice with chronic TNBS colitis. Colonic Tgf-β1 mRNA expression was not affected by intracolonic mCRAMP peptide administration. Per group, n = 6 mice.](gr1){#fig1}

![**Cathelicidin administration does not affect macrophage infiltration in colonic tissues: immunohistochemistry of macrophage marker F4/80 in colonic tissues.** Macrophages are identified by brown staining (*arrows*). TNBS-treated mice had increased F4/80 immunostaining compared with the ethanol control group. Intracolonic mCRAMP treatment did not affect F4/80-expressing macrophage infiltration in TNBS-treated mice.](gr2){#fig2}

![**Cathelicidin peptide administration reduces colonic collagen deposition in mice with chronic TNBS colitis.** (*A*) Masson Trichrome staining for collagen in colonic tissues. Collagen was stained in blue with a red background. Collagen deposited in the mucosal and submucosal layer of TNBS-treated mice was reduced by mCRAMP peptide treatment. (*B*) Fibrosis score of colonic tissues. The elevated fibrosis score of TNBS-treated mice (*P* = .0001) was statistically significantly reduced by mCRAMP peptide treatment (*P* = .0001). (*C*) Quantitative real-time RT-PCR of collagen col1a2 mRNA expression in colonic tissues of mice. TNBS treatment statistically significantly induced colonic col1a2 mRNA (*P* = .0376) expression. Intracolonic treatment of mCRAMP reduced colonic col1a2 mRNA expression (*P* = .0364). Per group, n = 6 mice.](gr3){#fig3}

![**Cathelicidin reduces collagen expression in colonic fibroblasts: immunofluorescence staining of collagen (*red*), fibroblast marker vimentin (*green*), and nuclei DAPI (*blue*).** In TNBS + TFA, intense red collagen staining was observed in and around fibroblasts that were identified by green color. Overlapping images of red collagen staining and green vimentin staining resulted in a yellowish color (*lower right corner*), indicating colocalization of collagen expression in fibroblasts. The TNBS + mCRAMP treatment group and the ethanol group had a low level of collagen staining in and around the vimentin green staining, indicating low collagen expression in fibroblasts.](gr4){#fig4}

![**Intracolonic cathelicidin peptide administration reduces colonic collagen deposition in cathelicidin-deficient mice with chronic TNBS colitis.** (*A*) Representative H&E images of colonic tissues. (*B*) Histology score based on H&E staining images of colonic tissues. TNBS treatment in *Camp*^−/−^ mice led to increased tissue damage with a statistically significantly higher histology score (*P* = .001) compared with the ethanol control. Peptide treatment of mCRAMP statistically significantly reduced the histology score in *Camp*^−/−^ mice (*P* = .04). (*C*) Masson Trichrome staining for collagen in colonic tissues. Collagen was stained in blue. Collagen deposited in mucosal and submucosal layer of TNBS treated *Camp*^−/−^ mice was reduced by mCRAMP peptide treatment. (*D*) Quantitative real-time RT-PCR of collagen col1a2 mRNA expression in colonic tissues of mice. TNBS treatment statistically significantly induced colonic col1a2 mRNA (*P* = .0311) expression. Intracolonic treatment of mCRAMP reduced colonic col1a2 mRNA expression in *Camp*^−/−^ (*P* = .04) mice. (*E*) TNBS treatment statistically significantly induced colonic Tnfα protein (*P* = .0042 in wild-type; *P* = .0241 in *Camp*^−/−^ mice) expression. Intracolonic mCRAMP administration statistically significantly reduced TNBS-induced Tnfα protein expression in *Camp*^−/−^ (*P* = .0054) mice. Per group, n = 6 mice.](gr5){#fig5}

![**Lentiviral cathelicidin expression reduces colonic inflammation in TNBS-mediated chronic colitis in mice.** (*A*) Illustration of experimental plan of TNBS-mediated chronic colitis with LV vector protocol. Mice were injected with increasing doses of TNBS solution intracolonically once a week for 6 weeks as described in *Methods*. Some mice received intravenous injection of mouse cathelicidin *Camp*-HA-expressing lentivirus or HA-expressing lentivirus (control), starting from the fifth TNBS injection. Colonic changes were evaluated 1 week after the last TNBS injection. (*B*) Colonic *Camp* mRNA expression was statistically significantly increased in the *Camp*-LV group (*P* = .026 and *P* = .0413). (*C*) Representative H&E images of colonic tissues. (*D*) Histology score based on H&E staining images of colonic tissues. TNBS treatment in mice led to increased tissue damage with a statistically significantly higher histology score (*P* = .001) compared with the ethanol control. Treatment of *Camp*-LV statistically significantly reduced the histology score (*P* = .0034). (*E*) Percentage of body weight change of different groups (from week 0 to week 6). Cathelicidin-expressing LV infection did not alter mice body weight. Per group, n = 6 mice.](gr6){#fig6}

![**Lentiviral cathelicidin expression reduces colonic collagen deposition in mice with chronic TNBS colitis.** (*A*) Masson Trichrome staining for collagen in colonic tissues. Collagen deposited in the mucosal and submucosal layer of TNBS-treated mice was reduced by *Camp*-expressing LV treatment. (*B*) Fibrosis score of colonic tissues. The elevated fibrosis score of TNBS-treated mice was statistically significantly reduced by *Camp*-expressing lentivirus treatment (*P* = .0001). (*C*) Colonic col1a2 mRNA expression was statistically significantly reduced in *Camp*-lentivirus group (*P* = .0497). Per group, n = 6 mice.](gr7){#fig7}

![**Lentiviral cathelicidin expression reduces colonic inflammation in *Salmonella*-induced cecal inflammation in mice.** (*A*) Illustration of the experimental plan of *Salmonella*-mediated cecal inflammation with LV vector protocol. Mice were fed with streptomycin to reduce the microflora load in the intestine and facilitate infection, and 24 hours later, the mice were inoculated with *Salmonella*. Some mice received intravenous injection of mouse cathelicidin *Camp*-HA-expressing lentivirus or control lentivirus on day 11. Cecal changes were evaluated on day 21. (*B*) Cecal *Camp* mRNA expression was statistically significantly increased in the *Salmonella*-infected group and was further augmented in the *Camp*-LV group (*P* = .0001 and *P* = .0317). (*C*) Representative H&E images of colonic tissues. (*D*) Histology score was based on H&E staining images of colonic tissues. TNBS treatment in mice led to increased tissue damage with a statistically significantly higher histology score (*P* = .0001) compared with the ethanol control. Treatment of *Camp*-LV statistically significantly reduced histology score (*P* = .0001). (*E*) *Salmonella* infection statistically significantly induced cecal Tnfα mRNA (*P* = .0001) expression. *Camp*-lentivirus treatment significantly reduced *Salmonella* induced Tnfα mRNA (*P* = .0107) expression. Per group, n = 6.](gr8){#fig8}

![**Lentiviral cathelicidin expression reduces colonic collagen deposition in mice with *Salmonella*-induced cecal fibrosis.** (*A*) Percentage of body weight change of different groups (from day 0 to day 21). *Salmonella*- or cathelicidin-expressing LV infection did not alter the body weight of mice. (*B*) Masson Trichrome staining for collagen in colonic tissues. Collagen deposited in mucosal and submucosal layers of *Salmonella*-infected mice was reduced by *Camp*-expressing lentivirus treatment. (*C*) Fibrosis score of colonic tissues. The elevated fibrosis score of *Salmonella*-infected mice was statistically significantly reduced by *Camp*-expressing LV treatment (*P* = .0001). (*D*) Colonic col1a2 mRNA expression was statistically significantly reduced in the *Camp*-lentivirus group (*P* = .0251). (*E*) Cecal Tgf-β1 mRNA expression in mice with *Salmonella* infection. *Salmonella* infection increased the cecal Tgf-β1 mRNA expression (*P* = .0091), but the increase was not affected by *Camp*-lentivirus. Per group, n = 6 mice.](gr9){#fig9}

![**Cathelicidin reduces collagen expression in human primary intestinal fibroblasts.** (*A* and *B*) Human primary intestinal fibroblasts isolated from normal subjects were treated with TGF-β1 (50 ng/mL) and IGF-1 (10 ng/mL) or TGF-β1 (5 ng/mL) alone with or without LL-37 for 48 hours. Western blot analyses showed that TGF-β1 (*P* = .0001) alone induced pro-COL1A1 protein expression. LL-37 (5 μM) statistically significantly suppressed collagen expression in the presence of TGF-β1 alone (*P* = .0001). (*C*) Serum-starved human primary normal intestinal fibroblasts were exposed to TFA, LL-37 (5 μM), and/or TGF-β1 (5 ng/mL) for 16 hours. LL-37 statistically significantly inhibited collagen mRNA expression induced by TGF-β1. (*D* and *E*) Human primary intestinal fibroblasts from a CD patient were treated with TGF-β1 (50 ng/mL) and IGF-1 (10 ng/mL) together or TGF-β1 (5 ng/mL) alone with or without LL-37 (0--3 μM) for 48 hours. Western blot analyses showed that both TGF-β1 (50 ng/mL) and IGF-1 (10 ng/mL) together and TGF-β1 (5 ng/mL) alone induced pro-COL1A1 protein expression. LL-37 (3 μM) statistically significantly suppressed collagen expression in the presence of TGF-β1 and/or IGF-1 (*P* = .0001). The results are representative of three healthy individuals and two CD patients.](gr10){#fig10}

![**Cathelicidin reduces collagen expression in human CCD-18Co colonic fibroblasts.** (*A* and *B*) Human colonic CCD-18Co fibroblasts were incubated with TGF-β1 (50 ng/mL) and IGF-1 (10 ng/mL) or TGF-β1 (5 ng/mL) alone with or without LL-37 for 8 hours. Western blot analyses showed that TGF-β1 and IGF-1 together (*P* = .0001) and TGF-β1 (*P* = .0001) alone induced pro-COL1A1 protein expression. LL-37 (5 μM) statistically significantly suppressed collagen expression in the presence of TGF-β1 and IGF-1 together (*P* = .0001) or TGF-β1 alone (*P* = .0001). Results are representative of three independent experiments.](gr11){#fig11}

![**Antifibrogenic effect of cathelicidin is ERK dependent.** (*A*) Human primary normal intestinal fibroblasts were pretreated with dimethyl sulfoxide, MEK1 inhibitor PD98059 (10 μM), or MEK1/2 inhibitor U0126 (10 μM) for 30 minutes, followed by LL-37 (5 μM) or TFA 0.1% and/or TGF-β1 (5 ng/mL) exposure for 48 hours. Pro-COL1A1 and GAPDH protein expression was detected by Western blot. Blockade of ERK partially reversed the antifibrogenic effects of cathelicidin. (*B*) Human primary normal intestinal fibroblasts were exposed to LL-37 (1--10 μM) or TFA 0.1% and/or TGF-β1 (50 ng/mL) and IGF-1 (10 ng/mL) together or TGF-β1 (5 ng/mL) alone for 30 minutes. Cathelicidin activated ERK phosphorylation in human fibroblasts.](gr12){#fig12}

![**Epidermal growth factor--mediated MAP kinase activation promotes the antifibrogenic effects of cathelicidin.** (*A*) Serum-starved CCD-18Co fibroblasts were exposed to 5 μM of LL-37 (0--30 minutes) or EGF (500 ng/mL, 30 minutes). Protein lysate was used for Western blot analyses. LL-37 induced the phosphorylation of ERK but not EGFR. EGF (as a positive control) induced both ERK and EGFR phosphorylation. (*B*) Serum-starved human primary intestinal fibroblasts were exposed to TFA, LL-37 (1--3 μM), or EGF (500 ng/mL) for 48 hours. Collagen protein expression was determined by Western blot analysis. (*C*) Quantitative analysis of the Western blot. EGF statistically significantly promoted cathelicidin-mediated inhibition of collagen expression in fibroblasts (LL-37 1 μM, *P* = .0001; LL-37 3 μM, *P* = .0001). (*D*) Serum-starved CCD-18Co colonic fibroblasts were exposed to TFA, LL-37 (3--5 μM), or EGF (500 ng/mL) for 8 hours. Collagen protein expression was determined by Western blot analysis. (*E*) Quantitative analysis of the Western blot. EGF statistically significantly promoted cathelicidin-mediated inhibition of collagen expression in fibroblasts (LL-37 3 μM, *P* = .0001; LL-37 5 μM, *P* = .0001). The results are representative of two independent experiments.](gr13){#fig13}

![**Cathelicidin activates ERK phosphorylation in submucosal tissue in vivo.** (*A*) Immunohistochemistry of phospho-ERK in mouse colons. Both normal control and TNBS-treated groups had low phospho-ERK signal in submucosal tissue. TNBS-treated mice with intracolonic mCRAMP peptide administration or intravenous *Camp*-expressing lentivirus administration had more phospho-ERK signal. (*B*) Immunohistochemistry of phospho-ERK in mouse cecum. Both normal control and *Salmonella*-treated groups had a low phospho-ERK signal in submucosal tissue. *Salmonella*-treated mice with intravenous *Camp*-expressing LV administration had more phospho-ERK signal. Per group, n = 6 mice.](gr14){#fig14}

![**Cathelicidin does not affect TGF-β1 expression in fibroblasts.** (*A*) CCD-18Co fibroblasts were treated with proinflammatory cytokine cocktail with or without LL-37 for 48 hours. TGF-β1 protein secretion from CCD-18Co was not affected by cathelicidin. (*B*) TGF-β1 protein remaining in the cell lysate was not affected by cathelicidin. The results are representative of three independent experiments.](gr15){#fig15}
